Spyre Therapeutics Launches New $500M At-The-Market Offering, Upsizing Previous Program

summarizeSummary

Spyre Therapeutics launched a new At-The-Market (ATM) offering to sell up to $500 million of common stock, replacing a smaller prior program. The capital will fund ongoing clinical trials and R&D.

check_boxKey Events

• New At-The-Market (ATM) Offering

  Spyre Therapeutics established a new ATM program to sell up to $500 million of common stock through TD Securities (USA) LLC (TD Cowen).

• Upsized Capital Raise

  This new program replaces a previous ATM offering (which had $36.55 million in unsold securities carried forward from a February 2026 registration), significantly increasing the potential capital available to the company.

• Funding for Clinical Programs

  Proceeds will primarily fund preclinical studies, clinical trials, and manufacturing for its IBD and RD antibody programs, as well as general corporate purposes.

• Potential Share Dilution

  The offering is expected to result in immediate and substantial dilution for existing shareholders, as disclosed in the filing.

auto_awesomeAnalysis

Spyre Therapeutics has established a new At-The-Market (ATM) offering program to sell up to $500 million in common stock. This new program replaces a prior ATM offering, significantly increasing the potential capital available to the company. The proceeds are earmarked to advance its IBD and RD antibody programs, including funding preclinical studies, clinical trials, and manufacturing. This substantial capital raise, following recent positive Phase 2 clinical data for SPY001 and SPY002, provides a significant runway for the company's drug development efforts, although it will result in dilution for existing shareholders.